Human IL-17RC Antibody Summary
Leu21-Ala454
Accession # NP_116121
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of IL‑17 RC in K562 Human Cell Line by Flow Cytometry. K562 human chronic myelogenous leukemia cell line was stained with Mouse Anti-Human IL-17 RC Monoclonal Antibody (Catalog # MAB22691, filled histogram) or isotype control antibody (Catalog # MAB0041, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0101B).
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-17RC
IL-17 receptor C (IL-17 RC; also known as IL-17 RL and IL-17 Rhom) is an 85‑110 kDa member of the IL-17 receptor family. This is one of five families that currently comprise the cytokine receptor superfamily (1, 2, 3, 4, 5, 6). At this time, there are five members within the IL-17 receptor family, and these are termed IL-17 RA, B, C, D and E. Not all receptors appear to bind known members of the IL-17 cytokine family. To date, IL-17 RA is reported to bind IL-17(A), while IL-17 RB is reported to bind IL-17B and IL-17E (2, 4). Human IL-17 RC is a type I transmembrane glycoprotein that is expressed on a variety of nonhematopoietic cell types. These include endothelial cells (6, 7), chondrocytes and osteoblasts (8), breast and prostatic epithelium (6), and fibroblasts, plus renal tubular epithelium and skeletal muscle cells (8, 9). Full-length IL-17 RC is synthesized as a 791 amino acid (aa) precursor (10, 11). It contains a 20 aa signal sequence, a 518 aa extracellular domain (ECD) (aa 21‑538), a 21 aa transmembrane segment, and a 232 aa cytoplasmic region. Although IL-17 RA has two fibrinogen-like regions in its ECD that contribute to its function, no such architecture has been identified in the ECD of IL-17 RC (12). Based on studies looking at exon deletions, a key ligand-binding site would appear to exist over aa 425‑441 (13). The gene for human IL-17 RC contains 19 exons. It is estimated that there are over 90 alternative splice forms, with transmembrane-containing isoforms predominating (6, 14). The full-length isoform is estimated to occur approximately 10% of the time, while the three most common isoforms, as a group, occur about 50% of the time. Based on limited information, alternative splicing appears to regulate ligand specificity (13). R&D Systems IL-17 RC corresponds to IL-17 RC isoform # 3, which shows deletions of aa 36‑106 and 264‑278 relative to the full-length form (10). Over the ECD, IL-17 RC isoform #3 is 68% aa identical to mouse IL-17 RC ECD. IL-17 RC is the cognate receptor for IL-17F, and binds IL-17A with similar affinity (13). With IL-17 RA, it forms a definitive receptor for both IL-17A and IL-17F. The stoichiometry is unclear; it may form a heterodimer with IL-17 RA, or a heterotrimer with a preexisting IL-17 RA homodimer (4, 9, 13, 15). The heteromeric nature of the receptor may be important given that the predominant form of the IL-17 cytokine is now considered to be an IL-17A:IL-17F heterodimer (4).
- Gaffen, S.L. et al. (2006) Vitam. Horm. 74:255.
- Weaver, C.T. et al. (2007) Annu. Rev. Immunol. 25:821.
- Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
- Shen, F. and S.L. Gaffen (2008) Cytokine 41:92.
- You, Z. et al. (2006) Cancer Res. 66:175.
- You, Z. et al. (2007) Neoplasia 9:464.
- Gerritsen, M.E. et al. (2003) Br. J. Pharmacol. 140:595.
- Kokubu, T. et. Al. (2008) J. Hictochem. Cytochem. 56:89.
- Toy, D. et al. (2006) J. Immunol. 177:36.
- GenBank Accession # Q96F46.
- Haudenschild, D. et al. (2002) J. Biol. Chem. 277:4309.
- Kramer, J.M. et al. (2007) J. Immunol. 179:6379.
- Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
- Haudenschild, D.R. et al. (2006) Prostate 66:1268.
- Kramer, J.M. et al. (2006) J. Immunol. 176:711.
Product Datasheets
Citations for Human IL-17RC Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
Authors: JW Bolt, AW van Kuijk, MBM Teunissen, D van der Co, S Aarrass, DM Gerlag, PP Tak, MG van de San, MC Lebre, LGM van Baarse
Biomedicines, 2022-01-29;10(2):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
TH17 cytokines induce human airway smooth muscle cell migration.
Authors: Chang Y, Al-Alwan L, Risse PA, Roussel L, Rousseau S, Halayko AJ, Martin JG, Hamid Q, Eidelman DH
J. Allergy Clin. Immunol., 2011-02-22;127(4):1046-53.e1-2.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IL-17RC Antibody
There are currently no reviews for this product. Be the first to review Human IL-17RC Antibody and earn rewards!
Have you used Human IL-17RC Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
